FDA approves MS drug Extavia
Novartis has received the FDA approval for its multiple sclerosis (MS) medicine Extavia. The drug has been approved for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. The therapy is also indicated for patients who have experienced a first clinical episode of MS and have features consistent with the disease as shown by magnetic resonance imaging.

The FDA has issued a warning for the anti-smoking drugs Chantix and Zyban as bizarre behavior, including suicide, has been seen in people taking these medicines. Both drugs will now carry “black box” labels warning informing people that those consuming these drugs should be closely watched for signs of suicidal thoughts, depression, hostility or other changes in behavior.
The FDA has approved a second oral rotavirus vaccine, called Rotarix, which is in liquid form and is given in a two-dose series to infants of 6 to 24 weeks of age. The rotavirus infection results in vomiting and diarrhea in children. The new vaccine provides protection against the G1, G3, G4, and G9 strains, which cause rotavirus gastroenteritis. The vaccine is manufactured by
Acomplia, the obesity drug manufactured by